Business
Chemours is a global chemistry company selling refrigerants, titanium dioxide pigment, fluoropolymer resins, and related specialty materials.
Chemours held FY2025 revenue roughly flat but swung to a large loss, while FCF turned positive and the CEO bought stock.
The read at a glance✓ Audited against SEC data
- Business mix — Specialty chemicalsNote
- Revenue — $5.808B, +0.4%Note
- Net income — ($386.0M), lossWatch
- FCF — $51.0M, positiveOK
- Equity — $250.0M, -56.2%Watch
- Insiders — $49.1K purchase and 0 salesOK
- Accounting — Altman N/A; Beneish clean; EQ safeOK
Where the revenue comes from
Fiscal 2025, as Chemours Co reports it. History and quarterly detail are in the app.
- Titanium Technologies$2.4B
- Thermal And Specialized Solutions$2.1B
- Advanced Performance Materials$1.3B
- Other Non-Reportable$50.0M
- All Other Segments$50.0M
Leadership changes
From Chemours Co's own filings, the day they're filed.
- Leslie M. Turner · Directors · appointmenteff. 2025-02-19
- Joseph D. Kava · Directors · appointmenteff. 2025-01-03
- David A. Will · Chief Accounting Officer · appointmenteff. 2024-08-12
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-05-05
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Chemours Co, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.